The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brian Abrahams - RBC Capital Markets - Analyst
: Hey guys, good morning, congrats on the data. Thanks for hosting us and thanks for taking my questions. Just a few for me. I guess, first, I
was wondering if you could maybe talk a little bit more about the persistence of the weight loss out the additional week, whether this is all
kind of related to that multi-day half-life or there's something else in the mechanism that leads to this persistence? And maybe if you can
talk about maybe any of the PK or exposure curve relationships to weight loss?
And then I'm also curious on the safety side, if you saw any sort of lab changes, any changes to vitals such as changes in body temperature
or patterns there? And then maybe just lastly, curious maybe if the panelists can talk about their views on how titration with this mechanism
could potentially impact the safety profile and therapeutic window?
Question: Felicia Berben - Piper Sandler - Analyst
: Thanks for taking my question. I was just hoping you could frame today's 2.9% placebo-adjusted weight loss at day 14 in the obesity cohorts
against expectations for the upcoming Phase 1b doses, particularly given the titration plan and the lower daily doses being selected?
And also just a question for Dr. Barenbaum. I was hoping you could just elaborate a bit more on where you see this fitting into your treatment
practice if CRB-913 makes it to market in several years, If there are certain patient subgroups where this might be most ideal to use?
Question: Graig Suvannavejh - Mizuho Americas LLC - Analyst
: Can you hear me okay now?
Question: Graig Suvannavejh - Mizuho Americas LLC - Analyst
: Thanks so much for this presentation and congrats on the data. I'm just wondering, we saw some differences in anxiety between obese
and non-obese patients. I was wondering if there was an explanation? Is that just random chance? Any thoughts there?
LSEG STREETEVENTS | www.lseg.com | Contact Us
consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.
Question: Graig Suvannavejh - Mizuho Americas LLC - Analyst
: And Dr. Barenbaum or Dr. Lee want to come in with an opinion?
Question: Graig Suvannavejh - Mizuho Americas LLC - Analyst
: And then...
Question: Graig Suvannavejh - Mizuho Americas LLC - Analyst
: If I could just ask -- yes, if I could ask a follow-up maybe for Dr. Barenbaum. We are seeing across the industry, so many different new
products, new mechanisms. I hear you on looking for additional mechanisms that go beyond perhaps GLP-1-based mechanisms. But if you
look into the future or if you look into your crystal ball, is your current view that GLP-1s will be the go-to induction way of getting patients to
start losing weight and then perhaps other mechanisms coming in as a more maintenance type of treatment or just overall thoughts on
where novel mechanisms like a CB1 will fit?
I know it's early days, as you mentioned, but is it still going to be GLP-1 based to start off and then maybe looking to switch or add something
later on?
| 
